Antidiabetic agents: Do they hit the right targets?-Reference-Cited by-同舟云学术

Antidiabetic agents: Do they hit the right targets?

Published:2022-12-01 Issue:4 Volume:2 Page:225-243
ISSN:2719-8073
Container-title:Frigid Zone Medicine
language:en
Short-container-title:

Author:

Zhao Yongting¹²,Zhang Xiaofang¹,Liang Haihai³,Wang Lihong¹

Affiliation:

1. Department of Endocrinology , the First Affiliated Hospital of Jinan University , Guangzhou , China

2. Department of Endocrinology , The Second Affiliated Hospital of Harbin Medical University , Harbin , China

3. Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education) , College of Pharmacy , Harbin Medical University , Harbin , China

Abstract

Abstract Diabetes mellitus (DM) is a progressive metabolic disease characterized by chronic hyperglycemia and caused by different degree of pancreatic islet dysfunction and/or insulin resistance (IR). Long course DM can lead to a variety of macrovascular and microvascular complications which involve artery vessels, heart, kidney, retina, nervous system, etc. In recent years, DM has attracted more and more attention due to its high morbidity and mortality. In addition to achieve effective glycemic control, prevention of complications has also been considered a priority for type 2 diabetes mellitus (T2DM) management. Herein, we provide a comprehensive overview on the pharmacotherapeutics for T2DM and perspectives on the future directions of basic and translational research on anti-diabetic therapy and pharmatheutical development of new drugs.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/fzm-2022-0030

Reference242 articles.

1. Benito-Vicente A, Jebari S, Larrea-Sebal A, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci, 2020; 21(17): 6275.

2. Chatterjee S, Khunti K, Davies M J. Type 2 diabetes. Lancet, 2017; 389(10085): 2239–2251.

3. Stumvoll M, Goldstein B J, van Haeften T W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 2005; 365(9467): 1333–1346.

4. Yoon K H, Lee J H, Kim J W, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet, 2006; 368(9548): 1681–1688.

5. Weyer C, Bogardus C, Mott D M, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest, 1999; 104(6): 787–794.